Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 0.40 |
| ▸ | ESR1 | P03372 | 12/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865594 | 1.00 | ESR2 (0.40) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL6866518 | 0.86 | ESR2 (0.44) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL6866516 | 0.86 | ESR2 (0.44) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL6867018 | 0.81 | ALDH1A1 (0.38) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6870181 | 0.78 | HSP90AB1 (0.49) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6864329 | 0.77 | ESR2 (0.41) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL6864333 | 0.77 | ESR2 (0.41) | ESR2ESR1KDM4EALDH1A1HPGD | |
| SCHEMBL6867902 | 0.76 | ESR2 (0.47) | ESR2ESR1 | |
| SCHEMBL6867899 | 0.76 | ESR2 (0.47) | ESR2ESR1 | |
| SCHEMBL7706774 | 0.75 | ESR2 (0.44) | ESR2ESR1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812331-B2 | BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | ESR2 3671/4885ESR1 4629/4885KDM4E 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.